Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide oncologists with key information about a patient’s specific tumor — in people with breast cancer. “The Theralink assay for breast cancer may reveal therapeutic options for oncologists and in turn, may provide better outcomes for breast cancer patients,” Mick Ruxin, MD, president and CEO of Theralink, said in a press release. The new test uses…
You must be logged in to read/download the full post.
The post Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors appeared first on BioNewsFeeds.